



Nozin®

NOVA<sup>SM</sup>  
PROGRAMS

# REDUCING MRSA INFECTION RATES BY 96%<sup>1</sup> IS NOT EASY.

▶ We can help get you there.

Hundreds of facilities are achieving similar results. Hundreds more are developing programs now. Could your facility benefit too? Learn more about the Nozin NOVA<sup>SM</sup> programs and decide.



## Nozin introduces NOVA<sup>SM</sup> programs

### Proven MRSA / MSSA Colonization Risk Mitigation

#### Why do you need a colonization risk mitigation program?

Data shows that nasal colonization is the #1 risk factor for MRSA infection. Colonized patients are 14 - 20 times more likely to become infected, MRSA / MSSA combined kill 20,000 patients a year and 80% of those infections can be traced back the patient's own flora.

#### The Nozin NOVA<sup>SM</sup> approach

Nozin, leader in developing and implementing MRSA / MSSA risk mitigation programs, presents NOVA<sup>SM</sup>, a proprietary suite of tools and services, guided by experienced consultants and proven to reduce infection risks while improving patient care.

In working with hospital partners across the country, the Nozin team has proven that facilities need these tools and services to help design, execute and sustain programs that improve patient care and outcomes while reducing costs and burdens on staff.

#### Clinical evidence of efficacy

Reported outcomes from facilities using these programs include reduction of MRSA infection risks by up to 96%, decreased use of contact precautions by 40% and savings up to \$1.4 million in a year<sup>2</sup>.

#### NOVA<sup>SM</sup> programs utilize Active Source Control<sup>SM</sup> strategies

Facilities implementing Nozin Active Source Control<sup>SM</sup>, attacking pathogens at their source by using Nozin<sup>®</sup> Nasal Sanitizer<sup>®</sup> antiseptic, are reporting better infection reductions versus the traditional Active Surveillance Testing/Contact Precautions (AST/CP) strategies they are replacing.

Multiple recent studies demonstrate that Active Source Control<sup>SM</sup> based programs not only reduce infections, they also reduce direct costs. And with the support of the Nozin NOVA<sup>SM</sup> team, program design and implementation are no longer a heavy task.



# Numerous third party clinical evidence studies

Facilities with years of experience with our programs report their results:

**74%** reduction in MRSA bacteremia when replacing an ICU screen and isolate protocol with a hospital-wide universal decolonization.

Jimenez, A., Sposato, K., De Leon Sanchez, A., Williams, R., & Francois, R. (2019). Reduction of Hospital-Onset Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia in an Acute Care Hospital: Impact of Bundles and Universal Decolonization. *Open Forum Infectious Diseases*, 6(52), S268. <https://doi.org/10.1093/ofid/ofz360.635>

**\$1.4M** cost savings when replacing targeted screening, isolation and decolonization with mupirocin with universal daily decolonization for all patients.

Whitaker, J. (2019). A Safe, More Cost-Effective Protocol: Universal Decolonization vs. MRSA Screening and Contact Precautions. *Open Forum Infectious Diseases*, 6(52), S25. <https://doi.org/10.1093/ofid/ofz359.055>

**88%** decrease in isolation days when replacing contact precautions for MRSA colonized patients with nasal and body decolonization.

Christie, J., Wright, D., Liebowitz, J., & Stefanacci, P. (2020). Can a nasal and skin decolonization protocol safely replace contact precautions for MRSA-colonized patients? *American Journal of Infection Control*, 48(8), 922-924. <https://doi.org/10.1016/j.ajic.2019.12.016>

**\$457K** cost avoidance associated with 22 fewer SSI during 6-month trial.

Cernich, C. (2020). Universal Preoperative Antiseptic Nasal and Skin Decolonization for Reduction in SSI and Associated Costs. *American Journal of Infection Control*, 48(8), S50. <https://doi.org/10.1016/j.ajic.2020.06.065>

**98%** reduction in total hip SSIs when replacing screening and decolonization with mupirocin to pre- and post-operative decolonization with alcohol-based nasal antiseptic (Nozin®).

Stegmeier, H. (2019). Alcohol-Based Nasal Antiseptic as Part of a Bundle to Reduce the Incidence of Contact Precautions and Surgical Site Infections. *Open Forum Infectious Diseases*, 6(52), S446. <https://doi.org/10.1093/ofid/ofz360.1101>

**100%** reduction in MRSA bacteremia in an adult intensive care setting adding universal nasal decolonization with alcohol-based nasal antiseptic (Nozin®).

Reeves, L., Barton, L., Williams, J., Don Guimera, Williams, B., Hysmith, N., & Morton, J. (2020). Effectiveness of an Alcohol-Based Nasal Antiseptic in Reducing MRSA Bacteremia in an Adult Intensive Care Population. *Infection Control & Hospital Epidemiology*, 41(51), s206. <https://doi.org/10.1016/j.ajic.2020.06.065>

A free Nozin NOVA<sup>SM</sup> Assessment is the first step toward achieving similar results in your facility.

**Executive Summary**

Using our proprietary analysis tools and the information your team provided, we have modeled your current MRSA colonization risk mitigation program and compared it with our most comprehensive NOVA<sup>SM</sup> program to provide context. We are not making a program recommendation at this time. We will work with you to build a customized program if you decide to move forward with us. The results are summarized on the chart below:


	Current	NOVA <sup>SM</sup> Program
Patients screened for MRSA	7,276	0
Patients isolated for MRSA (+)	0	0
Patients MRSA (+) isolation days	2,522	0
MRSA (+) patients undecolonized/unprotected	2,181	0
Total MRSA (+) patients	1,776	0
MRSA (+) patients decolonized	0	1,776
Routine contact with MRSA (+) patients	128,360	0
MRSA (+) patients - undecolonized/unprotected	4,209	0
Nasal contact with uncolonized (MRSA (-)) patient	2,500,000	0
Direct Costs - screening + isolation	\$777,891	\$0
Nozin Product Costs (est.)		\$36,216
<b>Program Direct Savings (est.)</b>		<b>\$363,705</b>

**Current Program Assessment**

Prepared for - Jenny Garcia - IP Manager  
 Sample Hospital S&H  
 3200 University Dr  
 Coral Gables, FL 33146  
 Prepared by: Greg Kilgore NOVA<sup>SM</sup> Program

Nozin | GLOBAL LIFE TECHNOLOGIES

## Anatomy of the #1 Daily Nasal Decolonizer



### NOVA<sup>SM</sup> Programs Use Nozin<sup>®</sup> Nasal Sanitizer<sup>®</sup> Antiseptic Exclusively. Nozin is the #1 Product for Daily Decolonization in Hospitals:

- Extensive published third party outcomes data
- Patented Nozaseptin<sup>®</sup> formula
- Fast, easy, pleasant application – preferred by staff and patients
- 99.99% pathogen knockdown
- Rechargeable 4X to assure complete decolonization of both nostrils
- 12-hour persistence
- Proprietary Popswab<sup>®</sup> delivery system

### Get your free Nozin NOVA<sup>SM</sup> Assessment today.

It's the first step toward these results for your facility. There is no cost, it takes very little of your staff's time, and it will reveal if you can reduce infection rates and costs and by how much. Then you can decide if developing a Nozin NOVA<sup>SM</sup> program is right for your facility. We can help you in your journey to zero MRSA infections.<sup>2</sup>



**Contact Nozin to learn more about NOVA<sup>SM</sup> programs.**

▶ Visit: [nozin.com/nova](http://nozin.com/nova)

▶ Call: 877-669-4648

1. Arden S. Does Universal Nasal Decolonization with an Alcohol-Based Nasal Antiseptic Reduce Infection Risk and Cost? Open Forum Infect Dis 2019 Oct; 6(Suppl 2): S26. 2. References list: [nozin.com/clinical-outcomes](http://nozin.com/clinical-outcomes). Outcomes reported by actual users. Your results may vary. Nozin<sup>®</sup> Nasal Sanitizer<sup>®</sup> antiseptic is for nasal decolonization. ©2021 Global Life Technologies Corp. All rights reserved. Made in USA. Nozin<sup>®</sup>, Nasal Sanitizer<sup>®</sup>, Popswab<sup>®</sup> and NOVA<sup>SM</sup> are trademarks of Global Life Technologies Corp. Nozin<sup>®</sup> Nasal Sanitizer<sup>®</sup> antiseptic is an OTC topical drug. No claim is made that it has an effect on any specific disease. Patent nos.: [nozin.com/patents](http://nozin.com/patents). ID: 1NOVA4B0630